Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Prepaid Assets (2023 - 2026)

Prelude Therapeutics' Prepaid Assets history spans 4 years, with the latest figure at $3.0 million for Q1 2026.

  • On a quarterly basis, Prepaid Assets fell 8.71% to $3.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.0 million, a 8.71% decrease, with the full-year FY2025 number at $2.5 million, up 8.64% from a year prior.
  • Prepaid Assets hit $3.0 million in Q1 2026 for Prelude Therapeutics, up from $2.5 million in the prior quarter.
  • Over the last five years, Prepaid Assets for PRLD hit a ceiling of $3.7 million in Q2 2025 and a floor of $2.3 million in Q4 2024.
  • Historically, Prepaid Assets has averaged $3.0 million across 4 years, with a median of $3.0 million in 2024.
  • Biggest five-year swings in Prepaid Assets: decreased 14.05% in 2024 and later grew 27.53% in 2025.
  • Tracing PRLD's Prepaid Assets over 4 years: stood at $2.7 million in 2023, then decreased by 14.05% to $2.3 million in 2024, then increased by 8.64% to $2.5 million in 2025, then grew by 22.64% to $3.0 million in 2026.
  • Business Quant data shows Prepaid Assets for PRLD at $3.0 million in Q1 2026, $2.5 million in Q4 2025, and $3.4 million in Q3 2025.